Home LiteratureArticle Details
PMID: 2932138 Published · ppublish English Clinical Trial Comparative Study Controlled Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

A comparison of three high doses of ipratropium bromide in chronic asthma.

British journal of diseases of the chest ·Vol. 79 ·No. 4 ·1985-10-00 ·Pages 379-84

Hockley B, Johnson NM

Abstract

We have performed a double-blind crossover study in nine patients with stable chronic asthma, in order to evaluate the effects of three doses of the anticholinergic bronchodilator ipratropium bromide (80 micrograms, 200 micrograms and 400 micrograms) given by metered dose inhaler. These doses are larger than the recommended dose (40 micrograms). All three doses of the drug produced significant bronchodilation from 15 minutes to 5 hours. Some small but statistically significant differences were found in favour of the 200 micrograms and 400 micrograms doses when compared with the 80 micrograms dose and the duration of action of the 400 micrograms dose was longer than that of 200 micrograms dose. The clinical usefulness of these small differences remains to be assessed.

MeSH Terms
Adult Aged Asthma/drug therapy Atropine Derivatives/administration & dosage Chronic Disease Clinical Trials as Topic Double-Blind Method Female Humans Ipratropium/administration & dosage,therapeutic use Male Middle Aged
Chemicals
Atropine Derivatives Ipratropium
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Hockley B
Johnson N M
Article Info
Journal
British journal of diseases of the chest
Abbr.
Br J Dis Chest
ISSN
0007-0971
Published
1985-10-00
Pages
379-84
Language
English
Region
England
NLM ID
7511123
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]